Rapport Therapeutics

RAPPNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$1.410 B

$23.78 -8.29%

Close of 6 Nov 2026

As of 6 Nov 2026, Rapport Therapeutics (RAPP) has a market capitalization of $1.41B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$111.5M

Loss-making

Shares outstanding

59,279,630

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#119Ocular TherapeutixOCUL$1.41B
#120Ascentage Pharma Group InternationalAAPG$1.41B
#121Rapport TherapeuticsRAPP$1.41B
#122ADARx PharmaceuticalsADRX$1.41B
#123Korsana BiosciencesKRSA$1.38B

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Rapport Therapeutics, worth $98.5K. Grants and option exercises are excluded.

Ramiro Sanchez$98.5K
3,600 shares at $27.35 on 23 Oct 2026 · filed 23 Oct 2026

What if Rapport Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$476,333.50

Per share 20,031× higher

Bitcoin $1.53T

$25,773.58

Per share 1,084× higher

Apple $5.02T

$84,612.25

Per share 3,558× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Rapport Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.